New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

References

• MitchisonDAThe diagnosis and therapy of tuberculosis during the past 100 yearsAm J Respir Crit Care Med2005171769970615709048
   PubMed Web of Science ®Google Scholar
• RaviglioneMCSniderDEKochiAGlobal epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemicJAMA199527332202267807661
   PubMed Web of Science ®Google Scholar
• DyeCGlobal epidemiology of tuberculosisLancet2006367951493894016546542
   PubMed Web of Science ®Google Scholar
• LienhardtCGlaziouPUplekarMLönnrothKGetahunHRaviglioneMGlobal tuberculosis control: lessons learnt and future prospectsNat Rev Microbiol201210640741622580364
   PubMed Web of Science ®Google Scholar
• RiederHLArnadottirTTrébucqAEnarsonDATuberculosis treatment: dangerous regimens?Int J Tuberc Lung Dis2001511311263509
   PubMed Web of Science ®Google Scholar
• World Health OrganizationMultidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and responseGenevaWorld Health Organization2010 Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdfAccessed June 13, 2014
   Google Scholar
• GandhiNRMollASturmAWExtensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaLancet200636895471575158017084757
   PubMed Web of Science ®Google Scholar
• BlumbergHMBurmanWJChaissonREAmerican Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases SocietyAmerican Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosisAm J Respir Crit Care Med2003167460366212588714
   PubMed Web of Science ®Google Scholar
• IsemanMDTreatment of multidrug-resistant tuberculosisN Engl J Med1993329117847918350889
   PubMed Web of Science ®Google Scholar
• LawKFJagirdarJWeidenMDBodkinMRomWNTuberculosis in HIV-positive patients: cellular response and immune activation in the lungAm J Respir Crit Care Med19961534 Pt 1137713848616569
   PubMed Web of Science ®Google Scholar
• NakataKRomWNHondaYMycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lungAm J Respir Crit Care Med1997155399610039117038
   PubMed Web of Science ®Google Scholar
• Abdool KarimSSNaidooKGroblerAIntegration of antiretroviral therapy with tuberculosis treatmentN Engl J Med2011365161492150122010915
   PubMed Web of Science ®Google Scholar
• BlancFXSokTLaureillardDCAMELIA (ANRS 1295–CIPRA KH001) Study TeamEarlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosisN Engl J Med2011365161471148122010913
   PubMed Web of Science ®Google Scholar
• HavlirDVKendallMAIvePAIDS Clinical Trials Group Study A5221Timing of antiretroviral therapy for HIV-1 infection and tuberculosisN Engl J Med2011365161482149122010914
   PubMed Web of Science ®Google Scholar
• BurmanWJGallicanoKPeloquinCComparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterialsClinical Pharmacokinetics200140532734111432536
   PubMed Web of Science ®Google Scholar
• Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [webpage on the Internet]AtlantaCenters for Disease Control and Prevention2013 Available from: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htmAccessed June 13, 2014
   Google Scholar
• NachegaJBRosenkranzBSimonGChaissonREDiaconATaljaardJManagement of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectivesInfect Disord Drug Targets201111213414321406051
   PubMedGoogle Scholar
• LeistikowRLMortonRABartekILFrimpongIWagnerKVoskuilMIThe Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancyJ Bacteriol201019261662167020023019
   PubMed Web of Science ®Google Scholar
• JindaniAAberVREdwardsEAMitchisonDAThe early bactericidal activity of drugs in patients with pulmonary tuberculosisAm Rev Respir Dis198012169399496774638
   PubMed Web of Science ®Google Scholar
• BoshoffHIBarryCE3rdTuberculosis – metabolism and respiration in the absence of growthNat Rev Microbiol200531708015608701
   PubMed Web of Science ®Google Scholar
• BennettDECourvalJMOnoratoIPrevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999–2000Am J Respir Crit Care Med2008177334835517989346
   PubMed Web of Science ®Google Scholar
• GlickmanSWRasielEBHamiltonCDKubataevASchulmanKAMedicine. A portfolio model of drug development for tuberculosisScience200631157651246124716513969
   PubMed Web of Science ®Google Scholar
• TB Alliance Interactive Portfolio [webpage on the Internet]Global Alliance for TB Drug Development Available from: http://www.tballiance.org/portfolio/Accessed February 21, 2014
   Google Scholar
• AndriesKVerhasseltPGuillemontJA diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosisScience2005307570722322715591164
   PubMed Web of Science ®Google Scholar
• HaagsmaACAbdillahi-IbrahimRWagnerMJSelectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologueAntimicrob Agents Chemother20095331290129219075053
   PubMed Web of Science ®Google Scholar
• HuitricEVerhasseltPAndriesKHoffnerSEIn vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitorAntimicrob Agents Chemother200751114202420417709466
   PubMed Web of Science ®Google Scholar
• KoulAVranckxLDendougaNDiarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasisJ Biol Chem200828337252732528018625705
   PubMed Web of Science ®Google Scholar
• PetrellaSCambauEChauffourAAndriesKJarlierVSougakoffWGenetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteriaAntimicrob Agents Chemother20065082853285616870785
   PubMed Web of Science ®Google Scholar
• GuptaSCohenKAWingleeKMaigaMDiarraBBishaiWREfflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosisAntimicrob Agents Chemother201458157457624126586
   PubMed Web of Science ®Google Scholar
• HartkoornRCUplekarSColeSTCross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosisAntimicrob Agents Chemother20145852979298124590481
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical CompaniesAnti-Infective Drugs Advisory Committee Meeting Briefing Document TMC207 (bedaquiline) Treatment of Patients with MDR-TB NDA 204-384Titusville, NJJanssen Pharmaceutical Companies2012 Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm329260.pdfAccessed February 21, 2014
   Google Scholar
• NuermbergerEMitchisonDAOnce-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibilityAm J Respir Crit Care Med200917912319098156
   PubMed Web of Science ®Google Scholar
• VezirisNIbrahimMLounisNA once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosisAm J Respir Crit Care Med20091791757918948422
   PubMed Web of Science ®Google Scholar
• RustomjeeRDiaconAHAllenJEarly bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosisAntimicrob Agents Chemother20085282831283518505852
   PubMed Web of Science ®Google Scholar
• DiaconAHPymAGrobuschMThe diarylquinoline TMC207 for multidrug-resistant tuberculosisN Engl J Med2009360232397240519494215
   PubMed Web of Science ®Google Scholar
• BarryCE3rdUnorthodox approach to the development of a new antituberculosis therapyN Engl J Med2009360232466246719494223
   PubMed Web of Science ®Google Scholar
• DiaconAHDawsonRVon Groote-BidlingmaierFRandomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAntimicrob Agents Chemother20135752199220323459487
   PubMed Web of Science ®Google Scholar
• LounisNVezirisNChauffourATruffot-PernotCAndriesKJarlierVCombinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment durationAntimicrob Agents Chemother200650113543354716954317
   PubMed Web of Science ®Google Scholar
• DiaconAHDonaldPRPymARandomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistanceAntimicrob Agents Chemother20125663271327622391540
   PubMed Web of Science ®Google Scholar
• Phase 2 open-label trial of TMC207 in an MDR-TB treatment regimen [webpage on the Internet]ParisInternational Union Against Tuberculosis and Lung Disease2011 Available from: http://uwclh.conference2web.com/content/1108Accessed February 21, 2014
   Google Scholar
• Anti-Infective Drugs Advisory Committee Meeting [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisory-Committee/UCM332961.pdfAccessed February 21, 2014
   Google Scholar
• Accelerated Approval Program [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2013 Available from: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm313768.htmAccessed February 21, 2014
   Google Scholar
• Sirturo™ [prescribing information]Titusville, NJJanssen Pharmaceutical Companies2012
   Google Scholar
• Janssen Infectious Diseases BVBAA study to evaluate the efficacy and safety of TMC207 in patients with pulmonary infection with multi-drug resistant Mycobacterium tuberculosis Available from: http://clinicaltrials.gov/ct2/show/NCT01600963?term=bedaquiline&rank=7. NLM identifier: NCT01600963Accessed February 21, 2014
   Google Scholar
• Centers for Disease Control and PreventionProvisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosisMMWR Recomm Rep201362RR-09112
   Google Scholar
• TasneenRLiSYPeloquinCASterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosisAntimicrob Agents Chemother201155125485549221930883
   PubMed Web of Science ®Google Scholar
• AvornJApproval of a tuberculosis drug based on a paradoxical surrogate measureJAMA2013309131349135023430122
   PubMed Web of Science ®Google Scholar